http://www.jcog.jp/basic/clinicaltrial/index.html Web日本神経内分泌腫瘍研究会
UMIN Clinical Trials Registry
WebJCOG1603INT RINDBeRG. Ramucirumab抵抗性進行胃癌に対するramucirumab+Irinotecan併用療法のインターグループランダム化第III相試験. ラムシルマブを含む化学療法に不応となった進行・再発胃癌・食道胃接合部癌を対象とし、イリノテカン+ラムシルマブ併用療法の ... WebUMIN-CTR Clinical Trial. Unique ID issued by UMIN. UMIN000014795. Receipt number. R000017173. Scientific Title. Randomized phase III study of etoposide plus cisplatin combination therapy versus irinotecan plus cisplatin combination therapy in advanced neuroendocrine carcinoma of the digestive system. (JCOG1213,TOPIC-NEC) illicits band
Current status of medical treatment for gastroenteropancreatic ...
WebAn observational retrospective-prospective analysis was conducted to investigate the usefulness of SSAs as first-line treatment for GEP-NETs, which identified primary pancreatic tumor, distant extrahepatic metastasis and non-resection of the primary tumor as predictors of a negative response to SSAs ( 23 ). http://csjarchive.cogsci.rpi.edu/Proceedings/2009/papers/331/paper331.pdf Web8 ago 2014 · JCOG1213 Coordinating Office National Cancer Center, Tokyo Hepatobiliary and Pancreatic Medical Oncology: scientific contact: Name: Okusaka Takuji: Address: 5-1-1. Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan : Telephone (+81)03-3542-2511: E-mail: [email protected]: Affiliation: National Cancer Center, Tokyo Hepatobiliary and … illicit response meaning